International Clinical Trial: A Phase Ib/II Clinical Trial of Anti-PD1/Anti-CTLA4 Antibodies Combined with Azacitidine and Venetoclax in Newly Diagnosed Elderly or Intensive Chemotherapy-Unfit Acute Myeloid Leukemia or Relapsed/Refractory Acute Myeloid Leukemia

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119729) titled 'A Phase Ib/II Clinical Trial of Anti-PD1/Anti-CTLA4 Antibodies Combined with Azacitidine and Venetoclax in Newly Diagnosed Elderly or Intensive Chemotherapy-Unfit Acute Myeloid Leukemia or Relapsed/Refractory Acute Myeloid Leukemia' on March 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sun Yat-Sen University Cancer Center

Condition: Acute myeloid leukemia

Intervention: Phase Ib trial group:QL1706 combined with azacitidine and venetoclax QL1706: Corresponding dose in the assigned dose group (4/5 mg/kg), IV, d1, d14 Azacitidine (AZA): 75 mg/m2, subcutaneous injection, d1-d7...